Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells

被引：49

作者：

Hoffman, TJ

Quinn, TP

Volkert, WA ^{[1
]}

机构：

[1] Univ Missouri, Dept Radiol, Columbia, MO 65211 USA

[2] Res Serv, Columbia, MO 65211 USA

[3] Univ Missouri, Dept Biochem, Columbia, MO 65211 USA

[4] Univ Missouri, Dept Internal Med, Columbia, MO 65211 USA

[5] HS Truman Mem VA Med Ctr, Columbia, MO 65211 USA

来源：

NUCLEAR MEDICINE AND BIOLOGY | 2001年 / 28卷 / 05期

关键词：

cancer; receptor-avid tracers; peptide conjugates; GRP receptors; alpha-MSH receptors; GC-C receptors;

D O I：

10.1016/S0969-8051(01)00209-8

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

New receptor-avid radiotracers are being developed for site-specific in vivo targeting of a myriad of receptors expressed on cancer cells. This review exemplifies strategies being used to design radiometallated peptide conjugates that maximize uptake in tumors and optimize their in vivo pharmacokinetic properties. Efforts to produce synthetic peptide analogues that target the following three receptor systems are highlighted: Gastrin releasing peptide (GRP), alpha-melanocyte stimulating hormone (alpha -MSH), and guanylate cyclase-C (GC-C) receptors. (C) 2001 Elsevier Science Inc. All rights reserved.

引用

页码：527 / 539

页数：13

共 103 条

[1]

Anderson C M, 1995, Oncology (Williston Park), V9, P1149

[2] Radiometal labeled agents (non-technetium) for diagnostic imaging [J].